Review Article
Antiangiogenic Therapy for Patients with Recurrent and Newly Diagnosed Malignant Gliomas
Table 1
Bevacizumab for recurrent or newly malignant gliomas.
| Study | Agents | Patients | RR | MPFS | 6-PFS | MST | Ref. |
| Phase II | Bevacizumab + irinotecan | 35 recurrent GBM | 57% | 6 months | 46% | 10.5 months | [11] | Phase II | Bevacizumab | 85 recurrent GBM | 28% | 4.2 months | 43% | 9.2 months | | Bevacizumab + irinotecan | 82 recurrent GBM | 38% | 5.6 months | 50% | 8.7 months |
[12] | Phase II | Bevacizumab | 48 recurrent GBM | 35% | 4 months | 29% | 7.7 months | [13] | Phase II | Bevacizumab + irinotecan | 23 recurrent GBM | 61% | 5.0 months | 30% | 10 months | | 9 recurrent AG | 67% | 7.5 months | 56% | Not reached |
[28] | Phase II | Bevacizumab + irinotecan | 33 recurrent AG | 61% | 7.5 months | 55% | 16.3 months | [29] | Retrospective | Bevacizumab + SRT | 20 recurrent GBM | 50% | 7.3 months | 65% | 12.5 months | [30] | 5 recurrent AG | 60% | 7.5 months | 60% | 16.5 months | Retrospective | SRS + bevacizumab | | — | 5.2 months | — | 11.2 months | [31] | SRS + other drugs |
49 recurrent GBM | — | 2.1 months | — | 3.9 months | Phase II | Bevacizumab + erlotinib | 25 recurrent GBM | 48% | 4.5 months | 28% | 10.5 months | | | 32 recurrent AG | 31% | 5.9 months | 44% | 17.8 months |
[32] | Phase II | Bevacizumab + RT/TMZ | 70 newly diagnosed GBM | — | 13.6 months | 88% | 19.6 months | [14] | Phase II | Bevacizumab + RT/TMZ | 125 newly diagnosed GBM | — | 13.8 months | 87% | — |
[15] | Phase II | Adjuvant bevacizumab | 125 newly diagnosed | | | | | | + irinotecan + TMZ | GBM |
— |
13.8 months |
— |
21.3 months |
[33] |
|
|
RR: response rate; MPFS: median progression-free survival; 6-PFS: 6-month progression-free survival; MST: median overall survival time; GBM: glioblastoma multiforme; AG: anaplastic gliomas; SRT: stereotactic radiotherapy; SRS: stereotactic radiosurgery; RT: radiotherapy; TMZ: temozolomide.
|